Therapeutic approaches for shankopathies

Developmental Neurobiology

Volumn 74, Issue 2, 2014, Pages 123-135

  Wang, Xiaoming ^a   Bey, Alexandra L ^a   Chung, Leeyup ^a   Krystal, Andrew D ^a   Jiang, Yong Hui ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autism spectrum disorders; Brain stimulation; Mouse model; SHANK family protein; Synapses

Indexed keywords

GLUTAMIC ACID;

ARTICLE; AUTISM; GENE MUTATION; GENETIC DISORDER; HUMAN; MULTIGENE FAMILY; NEUROMODULATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHANK GENE; SHANKOPATHY; SYNAPTIC POTENTIAL; TRANSCRANIAL MAGNETIC STIMULATION;

AUTISM SPECTRUM DISORDERS; BRAIN STIMULATION; MOUSE MODEL; SHANK FAMILY PROTEIN; SYNAPSES;

ANIMALS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; MUTATION; NERVE TISSUE PROTEINS; SYNAPTIC TRANSMISSION; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84891903357     PISSN: 19328451     EISSN: 10974695     Source Type: Journal    
DOI: 10.1002/dneu.22084     Document Type: Article

References (120)

1. Ahmed Z, Wieraszko A. 2006. Modulation of learning and hippocampal, neuronal plasticity by repetitive transcranial magnetic stimulation (rTMS). Bioelectromagnetics 27:288-294.
2. Aydin-Abidin S, Trippe J, Funke K, Eysel UT, Benali A. 2008. High- and low-frequency repetitive transcranial magnetic stimulation differentially activates c-Fos and zif268 protein expression in the rat brain. Exp Brain Res 188:249-261.
3. Bale TL, Baram TZ, Brown AS, Goldstein JM, Insel TR, McCarthy MM, et al. 2010. Early life programming and neurodevelopmental disorders. Biol Psychiatry 68:314-319.
4. Bangash MA, Park JM, Melnikova T, Wang D, Jeon SK, Lee D, Syeda S, et al. 2011. enhanced polyubiquitination of Shank3 and NMDA receptor in a mouse model of autism. Cell 145:758-772.
5. Beri S, Tonna N, Menozzi G, Bonaglia MC, Sala C, Giorda R. 2007. DNA methylation regulates tissue-specific expression of Shank3. J Neurochem 101:1380-1391.
6. Berkel S, Marshall CR, Weiss B, Howe J, Roeth R, Moog U, Endris V, Roberts W, Szatmari P, Pinto D, et al. 2010. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet 42:489-491.
7. Berkel S, Tang W, Trevino M, Vogt M, Obenhaus HA, Gass P, Scherer SW, Sprengel R, Schratt G, Rappold GA. 2012. Inherited and de novo SHANK2 variants associated with autism spectrum disorder impair neuronal morphogenesis and physiology. Hum Mol Genet 21:344-357.
8. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, et al. 2012. Effects of STX209 (Arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A Randomized, controlled, phase 2 trial. Sci Transl Med 4:152ra127.
9. Betancur C. 2011. Etiological heterogeneity in autism spectrum disorders: More than 100 genetic and genomic disorders and still counting. Brain Res 1380:42-77.
10. Bhattacharya A, Kaphzan H, Alvarez-Dieppa AC, Murphy JP, Pierre P, Klann E. 2012. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, behavioral phenotypes in fragile X syndrome mice. Neuron 76:325-337.
11. Blenner S, Reddy A, Augustyn M. 2011. Diagnosis and management of autism in childhood. BMJ 343:d6238.
12. Boccuto L, Lauri M, Sarasua SM, Skinner CD, Buccella D, Dwivedi A, Orteschi D, Collins JS, Zollino M, Visconti P, Dupont B, Tiziano D, Schroer RJ, Neri G, Stevenson RE, Gurrieri F, Schwartz CE et al., 2013. Prevalence of SHANK3 variants in patients with different subtypes of autism spectrum disorders. Eur J Hum Genet 21:310-316.
13. Bockers TM, Segger-Junius M, Iglauer P, Bockmann J, Gundelfinger ED, Kreutz MR, Richter D, Kindler S, Kreienkamp HJ. 2004. Differential expression and dendritic transcript localization of Shank family members: Identification of a dendritic targeting element in the 3' untranslated region of Shank1 mRNA. Mol Cell Neurosci 26:182-190.
14. Bonaglia MC, Giorda R, Beri S, De Agostini C, Novara F, Fichera M, Grillo L, et al. 2011. Molecular mechanisms generating and stabilizing terminal 22q13 deletions in 44 subjects with Phelan/McDermid syndrome. PLoS Genet 7:e1002173.
15. Bonaglia MC, Giorda R, Mani E, Aceti G, Anderlid BM, Baroncini A, Pramparo T, et al. 2005. Identification of a recurrent breakpoint within the SHANK3 gene in the 22q13.3 deletion syndrome. J Med Genet 43:822-828.
16. Bozdagi O, Sakurai T, Papapetrou D, Wang X, Dickstein DL, Takahashi N, Kajiwara Y, et al. 2010. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Autism 1:15.
17. Carrasco M, Volkmar FR, Bloch MH. 2012. Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: Evidence of publication bias. Pediatrics 129:e1301-1310.
18. Ching TT, Maunakea AK, Jun P, Hong C, Zardo G, Pinkel D, Albertson DG, et al. 2005. Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. Nat Genet 37:645-651.
19. Daily JL, Nash K, Jinwal U, Golde T, Rogers J, Peters MM, Burdine RD, et al. 2011. Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome. PLoS One 6:e27221.
20. Dawson G, Jones EJ, Merkle K, Venema K, Lowy R, Faja S, Kamara D, Murias M, Greenson J, Winter J, et al. 2012. Early behavioral intervention is associated with normalized brain activity in young children with autism. J Am Acad Child Adolesc Psychiatry 51:1150-1159.
21. Dawson G, Rogers S, Munson J, Smith M, Winter J, Greenson J, Donaldson A, et al. 2010. Randomized, controlled trial of an intervention for toddlers with autism: The Early Start Denver Model. Pediatrics 125:e17-e23.
22. Dawson G, Webb SJ, Carver L, Panagiotides H, McPartland J. 2004. Young children with autism show atypical brain responses to fearful versus neutral facial expressions of emotion. Dev Sci 7:340-359.
23. Devlin B, Scherer SW. 2012. Genetic architecture in autism spectrum disorder. Curr Opin Genet Dev 22:229-237.
24. Dolen G, Carpenter RL, Ocain TD, Bear MF. 2010. Mechanism-based approaches to treating fragile X. Pharmacol Ther 127:78-93.
25. Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF. 2007. Correction of fragile X syndrome in mice. Neuron 56:955-962.
26. Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, Nygren G, et al. 2007. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 39:25-27.
27. Durand CM, Perroy J, Loll F, Perrais D, Fagni L, Bourgeron T, Montcouquiol M, et al. 2011. SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin-dependent mechanism. Mol Psychiatry 17:71-84.
28. Enticott PG, Rinehart NJ, Tonge BJ, Bradshaw JL, Fitzgerald PB. 2010. A preliminary transcranial magnetic stimulation study of cortical inhibition and excitability in high-functioning autism and Asperger disorder. Dev Med Child Neurol 52:e179-183.
29. Esser SK, Huber R, Massimini M, Peterson MJ, Ferrarelli F, Tononi G. 2006. A direct demonstration of cortical LTP in humans: A combined TMS/EEG study. Brain Res Bull 69:86-94.
30. Funke K, Benali A. 2011. Modulation of cortical inhibition by rTMS-Findings obtained from animal models. J Physiol 589:4423-4435.
31. Gadalla KK, Bailey ME, Spike RC, Ross PD, Woodard KT, Kalburgi SN, Bachaboina L, et al. 2013. Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol Ther 21:18-30.
32. Gauthier J, Champagne N, Lafreniere RG, Xiong L, Spiegelman D, Brustein E, Lapointe M, et al. 2010. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc Natl Acad Sci USA 107:7863-7868.
33. Gauthier J, Spiegelman D, Piton A, Lafreniere RG, Laurent S, St-Onge J, Lapointe L, et al. 2009. Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B Neuropsychiatr Genet 150B, 421-424.
34. Georgiades S, Szatmari P, Boyle M, Hanna S, Duku E, Zwaigenbaum L, Bryson S, et al. 2012. Investigating phenotypic heterogeneity in children with autism spectrum disorder: A factor mixture modeling approach. J Child Psychol Psychiatry. 54, 206-215
35. Gersner R, Kravetz E, Feil J, Pell G, Zangen A. 2011. Long-term effects of repetitive transcranial magnetic stimulation on markers for neuroplasticity: Differential outcomes in anesthetized and awake animals. J Neurosci 31:7521-7526.
36. Geschwind DH. 2008. Autism: Many genes, common pathways? Cell 135:391-395.
37. Geschwind DH, Levitt P. 2007. Autism spectrum disorders: Developmental disconnection syndromes. Curr Opin Neurobiol 17:103-111.
38. Giacometti E, Luikenhuis S, Beard C, Jaenisch R. 2007. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci USA 104:1931-1936.
39. Grabrucker AM, Schmeisser MJ, Schoen M, Boeckers TM. 2011. Postsynaptic ProSAP/Shank scaffolds in the cross-hair of synaptopathies. Trends Cell Biol 21:594-603.
40. Grindle CF, Hastings RP, Saville M, Hughes JC, Huxley K, Kovshoff H, Griffith GM, et al. 2012. Outcomes of a behavioral education model for children with autism in a mainstream school setting. Behav Modif 36:298-319.
41. Guggenhuber S, Monory K, Lutz B, Klugmann M. 2010. AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neurons of the hippocampus protects against seizure-induced excitoxicity. PLoS One 5:e15707.
42. Gundelfinger ED, Boeckers TM, Baron MK, Bowie JU. 2006. A role for zinc in postsynaptic density asSAMbly and plasticity? Trends Biochem Sci 31:366-373.
43. Guy J, Gan J, Selfridge J, Cobb S, Bird A. 2007. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315:1143-1147.
44. Hamdan FF, Gauthier J, Araki Y, Lin DT, Yoshizawa Y, Higashi K, Park AR, et al. 2011. Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet 88:306-316.
45. Han S, Tai C, Westenbroek RE, Yu FH, Cheah CS, Potter GB, Rubenstein JL, et al. 2012. Autistic-like behaviour in Scn1a+/- mice and rescue by enhanced GABA-mediated neurotransmission. Nature 489:385-390.
46. Hayward D, Eikeseth S, Gale C, Morgan S. 2009. Assessing progress during treatment for young children with autism receiving intensive behavioural interventions. Autism 13:613-633.
47. Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR, Brynczka C, et al. 2012. Reversal of Disease-Related Pathologies in the Fragile X Mouse Model by Selective Activation of GABAB Receptors with Arbaclofen. Sci Transl Med 4:152ra128.
48. Hoogendam JM, Ramakers GM, Di Lazzaro V. 2010. Physiology of repetitive transcranial magnetic stimulation of the human brain. Brain Stimul 3:95-118.
49. Houdayer E, Degardin A, Cassim F, Bocquillon P, Derambure P, Devanne H. 2008. The effects of low- and high-frequency repetitive TMS on the input/output properties of the human corticospinal pathway. Exp Brain Res 187:207-217.
50. Huang HS, Allen JA, Mabb AM, King IF, Miriyala J, Taylor-Blake B, Sciaky N, et al. 2012. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature 481:185-189.
51. Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. 2005. Theta burst stimulation of the human motor cortex. Neuron 45:201-206.
52. Huffman LC, Sutcliffe TL, Tanner IS, Feldman HM. 2011. Management of symptoms in children with autism spectrum disorders: A comprehensive review of pharmacologic and complementary-alternative medicine treatments. J Dev Behav Pediatr 32:56-68.
53. Hung AY, Futai K, Sala C, Valtschanoff JG, Ryu J, Woodworth MA, Kidd FL, et al. 2008. Smaller dendritic spines, weaker synaptic transmission, but enhanced spatial learning in mice lacking Shank1. J Neurosci 28:1697-1708.
54. Hung AY, Sung CC, Brito IL, Sheng M. 2010. Degradation of postsynaptic scaffold GKAP and regulation of dendritic spine morphology by the TRIM3 ubiquitin ligase in rat hippocampal neurons. PLoS One 5:e9842.
55. Husain MM, Lisanby SH. 2011. Repetitive transcranial magnetic stimulation (rTMS): A noninvasive neuromodulation probe and intervention. J ECT 27:2.
56. Kasari C, Lawton K. 2010. New directions in behavioral treatment of autism spectrum disorders. Curr Opin Neurol 23:137-143.
57. Kelleher RJ 3rd, Bear MF. 2008. The autistic neuron: Troubled translation? Cell 135:401-406.
58. Kerr B, Soto CJ Saez, M Abrams A, Walz K, Young JI. 2012. Transgenic complementation of MeCP2 deficiency: Phenotypic rescue of Mecp2-null mice by isoform-specific transgenes. Eur J Hum Genet 20:69-76.
59. Kim EJ, Kim WR, Chi SE, Lee KH, Park EH, Chae JH, Park SK, et al. 2006. Repetitive transcranial magnetic stimulation protects hippocampal plasticity in an animal model of depression. Neurosci Lett 405:79-83.
60. Kreienkamp HJ. 2008. Scaffolding proteins at the postsynaptic density: Shank as the architectural framework. Handb Exp Pharmacol, 365-380.
61. Krueger DD, Bear MF. 2011. Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 62:411-429.
62. LeBlanc JJ, Fagiolini M. 2011. Autism: A "critical period" disorder? Neural Plast 2011:921680.
63. Leblond CS, Heinrich J, Delorme R, Proepper C, Betancur C, Huguet G, Konyukh M, et al. 2012. Genetic and Functional Analyses of SHANK2 Mutations Suggest a Multiple Hit Model of Autism Spectrum Disorders. PLoS Genet 8:e1002521.
64. Li S, Sun B, Nilsson MI, Bird A, Tarnopolsky MA, Thurberg BL, Bali D. 2012. Adjunctive beta2-agonists reverse neuromuscular involvement in murine Pompe disease. FASEB J. 27:34-44
65. Lim S, Naisbitt S, Yoon J, Hwang JI, Suh PG, Sheng M, Kim E. 1999. Characterization of the Shank family of synaptic proteins. Multiple genes, alternative splicing, and differential expression in brain and development. J Biol Chem 274:29510-29518.
66. Lord C, Bishop SL. 2009. The autism spectrum: Definitions, assessment and diagnoses. Br J Hosp Med (Lond) 70:132-135.
67. Malhotra D, Sebat J. 2012. CNVs: Harbingers of a rare variant revolution in psychiatric genetics. Cell 148:1223-1241.
68. Manfredsson FP, Mandel RJ. 2011. The development of flexible lentiviral vectors for gene transfer in the CNS. Exp Neurol 229:201-206.
69. Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, et al. 2011a. Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: Results from a 52-week, open-label study. J Child Adolesc Psychopharmacol 21:229-236.
70. Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, et al. 2011b. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: A 52-week, open-label, multicenter study. J Clin Psychiatry 72:1270-1276.
71. Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD, Johnson BE, et al. 2010. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466:253-257.
72. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, et al. 2002. Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321.
73. McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, Veenstra-Vanderweele J. 2011. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 127:e1312-1321.
74. Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, et al. 2012. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74:49-56.
75. Moessner R, Marshall CR, Sutcliffe JS, Skaug J, Pinto D, Vincent J, Zwaigenbaum L, et al. 2007. Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet 81:1289-1297.
76. Mueller C, Ratner D, Zhong L, Esteves-Sena M, Gao G. 2012. Production and discovery of novel recombinant adeno-associated viral vectors. Curr Protoc Microbiol Chapter 14:Unit14D 11.
77. Myers SM. 2007. The status of pharmacotherapy for autism spectrum disorders. Expert Opin Pharmacother 8:1579-1603.
78. Myers SM, Johnson CP. 2007. Management of children with autism spectrum disorders. Pediatrics 120:1162-1182.
79. Naisbitt S, Kim E, Tu JC, Xiao B, Sala C, Valtschanoff J, Weinberg RJ, et al. 1999. Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron 23:569-582.
80. Newpher TM, Ehlers MD. 2009. Spine microdomains for postsynaptic signaling and plasticity. Trends Cell Biol 19:218-227.
81. Oberman LM, Horvath JC, Pascual-Leone A. 2010. TMS: using the theta-burst protocol to explore mechanism of plasticity in individuals with Fragile X syndrome and autism. J Vis Exp. pii:2272
82. Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith DH. 2010. First do no harm: Promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry 19:124-137.
83. Peca J, Feliciano C, Ting JT, Wang W, Wells MF, Venkatraman TN, Lascola CD, et al. 2011. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472:437-442.
84. Pell GS, Roth Y, Zangen A. 2011. Modulation of cortical excitability induced by repetitive transcranial magnetic stimulation: Influence of timing and geometrical parameters and underlying mechanisms. Prog Neurobiol 93:59-98.
85. Peterchev AV, Murphy DL, Lisanby SH. 2011. Repetitive transcranial magnetic stimulator with controllable pulse parameters. J Neural Eng 8:036016.
86. Phelan K. 2007. 22q13.3 Deletion syndrome. In: Roberta A Pagon, Thomas C Bird, Cynthia R Dolan, Karen Stephens, editors. Genetest, E.-i.-c. Seattle; Internet.
87. Philippe A, Boddaert N, Vaivre-Douret L, Robel L, Danon-Boileau L, Malan V, de Blois MC, et al. 2008. Neurobehavioral profile and brain imaging study of the 22q13.3 deletion syndrome in childhood. Pediatrics 122:e376-e382.
88. Rossi S, Hallett M, Rossini PM, Pascual-Leone A. 2009. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 120:2008-2039.
89. Rossini PM, Rossi S. 2007. Transcranial magnetic stimulation: Diagnostic, therapeutic, and research potential. Neurology 68:484-488.
90. Roussignol G, Ango F, Romorini S, Tu JC, Sala C, Worley PF, Bockaert J, et al. 2005. Shank expression is sufficient to induce functional dendritic spine synapses in aspiny neurons. J Neurosci 25:3560-3570.
91. Rubenstein JL. 2010. Three hypotheses for developmental defects that may underlie some forms of autism spectrum disorder. Curr Opin Neurol 23:118-123.
92. Sala C, Piech V, Wilson NR, Passafaro M, Liu G, Sheng M. 2001. Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Neuron 31:115-130.
93. Sato D, Lionel AC, Leblond CS, Prasad A, Pinto D, Walker S, O'Connor I, et al. 2012. SHANK1 Deletions in Males with Autism Spectrum Disorder. Am J Hum Genet 90:879-887.
94. Schmeisser MJ, Ey E, Wegener S, Bockmann J, Stempel AV, Kuebler A, Janssen AL, et al. 2012. Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2. Nature 486:256-260.
95. Sheng M, Kim E. 2000. The Shank family of scaffold proteins. J Cell Sci 113 (Pt 11), 1851-1856.
96. Shepherd GM, Katz DM. 2011. Synaptic microcircuit dysfunction in genetic models of neurodevelopmental disorders: Focus on Mecp2 and Met. Curr Opin Neurobiol 21:827-833.
97. Silverman JL, Smith DG, Rizzo SJ, Karras MN, Turner SM, Tolu SS, Bryce DK, Smith DL, Fonseca K, Ring RH, et al. 2012. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med 4:131ra151.
98. Silverman JL, Turner SM, Barkan CL, Tolu SS, Saxena R, Hung AY, Sheng M, et al. 2011. Sociability and motor functions in Shank1 mutant mice. Brain Res 1380:120-137.
99. Smith DG and Ehlers MD. 2012. Mining and modeling human genetics for autism therapeutics. Curr Opin Neurobiol 22:902-910.
100. Stanford AD, Corcoran C, Bulow P, Bellovin-Weiss S, Malaspina D, Lisanby SH. 2011. High-frequency prefrontal repetitive transcranial magnetic stimulation for the negative symptoms of schizophrenia: A case series. J ECT 27:11-17.
101. State MW. 2010. The genetics of child psychiatric disorders: Focus on autism and Tourette syndrome. Neuron 68:254-269.
102. Sun B, Young SP, Li P, Di C, Brown T, Salva MZ, Li S, et al. 2008. Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy. Mol Ther 16:1366-1371.
103. Taylor JL, McPheeters ML, Sathe NA, Dove D, Veenstra-Vanderweele J, Warren Z. 2012. A systematic review of vocational interventions for young adults with autism spectrum disorders. Pediatrics 130:531-538.
104. Toro R, Konyukh M, Delorme R, Leblond C, Chaste P, Fauchereau F, Coleman M, et al. 2010. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet 26:363-372.
105. Verpelli C, Dvoretskova E, Vicidomini C, Rossi F, Chiappalone M, Schoen M, Di Stefano B, et al. 2011. Importance of shank3 in regulating metabotropic glutamate receptor 5 (mGluR5) expression and signaling at synapses. J Biol Chem. 286:34839-34850
106. Vismara LA, Rogers SJ. 2010. Behavioral treatments in autism spectrum disorder: What do we know? Annu Rev Clin Psychol 6:447-468.
107. Volkmar FR. 2001. Pharmacological interventions in autism: Theoretical and practical issues. J Clin Child Psychol 30:80-87.
108. Volkmar FR, State M, Klin A. 2009. Autism and autism spectrum disorders: Diagnostic issues for the coming decade. J Child Psychol Psychiatry 50:108-115.
109. Waga C, Okamoto N, Ondo Y, Fukumura-Kato R, Goto Y, Kohsaka S, Uchino S. 2011. Novel variants of the SHANK3 gene in Japanese autistic patients with severe delayed speech development. Psychiatr Genet 21:208-211.
110. Wang X, McCoy P, Rodriguiz RM, Pan Y, Je HS, Roberts A, Kim C, et al. 2011. Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum Mol Genet. 20:3093-3108
111. Warren Z, McPheeters ML, Sathe N, Foss-Feig JH, Glasser A, Veenstra-Vanderweele J. 2011. A systematic review of early intensive intervention for autism spectrum disorders. Pediatrics 127:e1303-e1311.
112. Wassermann EM, Lisanby SH. 2001. Therapeutic application of repetitive transcranial magnetic stimulation: A review. Clin Neurophysiol 112:1367-1377.
113. Wilson HL, Wong AC, Shaw SR, Tse WY, Stapleton GA, Phelan MC, Hu S, et al. 2003. Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet 40:575-584.
114. Wohr M, Roullet FI, Hung AY, Sheng M, Crawley JN. 2011. Communication impairments in mice lacking Shank1: Reduced levels of ultrasonic vocalizations and scent marking behavior. PLoS One 6:e20631.
115. Wolff JJ, Gu H, Gerig G, Elison JT, Styner M, Gouttard S, Botteron KN, et al. 2012. Differences in White Matter Fiber Tract Development Present From 6 to 24 Months in Infants With Autism. Am J Psychiatry. 169:589-600
116. Won H, Lee HR, Gee HY, Mah W, Kim JI, Lee J, Ha S, et al. 2012. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 486:261-265.
117. Yang M, Bozdagi O, Scattoni ML, Wohr M, Roullet FI, Katz AM, Abrams DN, Kalikhman D, Simon H, Woldeyohannes L, et al. 2012. Reduced excitatory neurotransmission and mild autism-relevant phenotypes in adolescent Shank3 null mutant mice. J Neurosci 32: 6525-6541.
118. Zoghbi HY. 2003. Postnatal neurodevelopmental disorders: Meeting at the synapse? Science 302:826-830.
119. Zoghbi HY. 2005. MeCP2 dysfunction in humans and mice. J Child Neurol 20:736-740.
120. Zwaigenbaum L, Bryson S, Lord C, Rogers S, Carter A, Carver L, Chawarska K, et al. 2009. Clinical assessment and management of toddlers with suspected autism spectrum disorder: Insights from studies of high-risk infants. Pediatrics 123:1383-1391.